{
    "clinical_study": {
        "@rank": "18165", 
        "arm_group": [
            {
                "arm_group_label": "terlipressin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "norepinephrine", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of terlipressin for treating septic\n      shock."
        }, 
        "brief_title": "Continuos Terlipressin Infusion in Septic Shock", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Septic Shock", 
        "condition_browse": {
            "mesh_term": [
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Septic shock is the most common cause of death in intensive care units and has a mortality\n      rate of 40 to 60%.Vasopressin is commonly used as an adjunct to catecholamines to support\n      blood pressure in refractory septic shock.Recently small sample clinical study suggest that\n      Terlipressin,a vasopressin analogues, was effective in reversing sepsis-induced arterial\n      hypotension and in reducing norepinephrine requirements.But its effect on mortality is\n      unknown.Invesgators hypothesized that Terlipressin as compared with norepinephrine would\n      decrease mortality among patients with septic shock."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Septic shock was defined by the presence of two or more diagnostic criteria for the\n             systemic inflammatory responsesyndrome, proven or suspected infection, and\n             hypotension (exclusion of hypertention other than sepsis)\n\n        Exclusion Criteria:\n\n          -  organ transplantation;\n\n          -  pregancy or breast-feeding;\n\n          -  malignancy or other irreversible disease or condition for which has a poor prognosis;\n\n          -  acute coronary syndrome;\n\n          -  chronic heart failure(NYHA III or IV)/cardiogenic shock;\n\n          -  acute mesenteric ischemia;\n\n          -  greater than 48 hours had elapsed since the patient met entry criteria;\n\n          -  estimation of incomplite treament due to financial problem;\n\n          -  use of terlipressin for blood pressure support before entry;\n\n          -  Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;\n\n          -  registration of other clinical trial which will affect the outcome of the current\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697410", 
            "org_study_id": "2012A080204018;200705"
        }, 
        "intervention": [
            {
                "arm_group_label": "terlipressin", 
                "description": "continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure", 
                "intervention_name": "Terlipressin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "norepinephrine", 
                "description": "continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure", 
                "intervention_name": "Norepinephrine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Norepinephrine", 
                "Terlipressin", 
                "Lypressin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 27, 2012", 
        "location": {
            "contact": {
                "email": "carlg@163.net", 
                "last_name": "Guan Xiangdong, M.D.", 
                "phone": "862087555766-8456"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510000"
                }, 
                "name": "Surgical intensive care unit, 1st affiliated hospital of Sun Yat-sen university"
            }, 
            "investigator": {
                "last_name": "Guan Xiangdon, M.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter,Prospective,Randomized,Controlled,Double Blind Study in China to Evaluate the Effect of Terlipressin in Patients With Septic Shock", 
        "overall_contact": {
            "email": "carlg@163.net", 
            "last_name": "Guan Xiangdong, M.D.", 
            "phone": "862087755766-8456"
        }, 
        "overall_contact_backup": {
            "email": "sumslzm@163.com", 
            "last_name": "Liu Zimeng, M.D.", 
            "phone": "862087755766-8454"
        }, 
        "overall_official": [
            {
                "affiliation": "first affiliated hospital  SunYetSen university", 
                "last_name": "Guan XiangDong, doctor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "first affiliated hospital ,SunYetSen university", 
                "last_name": "liu ZiMeng, M.D", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "first affiliated hospital ,SunYetSen university", 
                "last_name": "Si Xiang, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "first affiliated hospital ,SunYetSen university", 
                "last_name": "Chen Juan, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion", 
            "measure": "28-day Mortality", 
            "safety_issue": "No", 
            "time_frame": "28-days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697410"
        }, 
        "responsible_party": {
            "investigator_affiliation": "First Affiliated Hospital, Sun Yat-Sen University", 
            "investigator_full_name": "Guan XiangDong", 
            "investigator_title": "director of surgical intensive care unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "SOFA score was measured on day0-7 after the start of the infusion in both groups", 
                "measure": "SOFA score", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Days of vasopressor  were recorded after the start of the infusion in both groups.", 
                "measure": "days alive and free of vasopressor", 
                "safety_issue": "No", 
                "time_frame": "during the first 28 days after the start of the infusion"
            }, 
            {
                "measure": "90-day mortality", 
                "safety_issue": "No", 
                "time_frame": "90 days after the start of the  infusion"
            }
        ], 
        "source": "First Affiliated Hospital, Sun Yat-Sen University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Guangdong Province, Department of  Science and Technology", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital, Sun Yat-Sen University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sixth Affiliated Hospital, Sun Yat-sen University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chinese PLA General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Beijing 302 Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shanghai Changzheng Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wuhan Union Hospital, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xiangya Hospital of Central South University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Anhui Provincial Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "First Affiliated Hospital Bengbu Medical College", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangxi Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Jinling Hospital, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "West China Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hainan People's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xi\u2019an Jiaotong University College of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "China Medical University, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "First People's Hospital of Foshan", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Zhuhai  People's Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "First Affiliated Hospital, Sun Yat-Sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}